Metabolite profiling of DFMO-treated ApcMin mouse tumors.

Slides:

Advertisements

Similar presentations

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Advertisements

Effects of senescent cells on activity.

Binding of 53BP1 on uncapped telomeres.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

BV6 increases tumor burden in bone.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

HER2 mutants V777L, G309A, D769H formed tumors more rapidly than HER2 WT. A, a total of 0.5 × 106 cells of NIH3T3 expressing either HER2 WT or mutant were.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Estrogen drives accumulation of myelomonocytic (M-MDSC) and granulocytic (G-MDSC) MDSCs and increases the immunosuppressive potential of G-MDSCs. Estrogen.

Fig. 6 Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing mice. Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing.

Effect of MI-773 and/or cisplatin in a preclinical model of ACC

Activity of MAC-321 (i. v. and p. o

Effect of MI-773 dosing on long-term efficacy.

In vivo growth inhibition elicited by afatinib and GSK in a CLU–NRG1-rearranged PDX mouse model. In vivo growth inhibition elicited by afatinib.

Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.

ONC201 activates the ISR. ONC201 activates the ISR. (A) Western blotting analysis for ATF4, CHOP, ATF3, and TRB3 on lysates from HCT116 cells cultured.

Metformin and rapamycin decreased tumor weights in obese prediabetic mice. Metformin and rapamycin decreased tumor weights in obese prediabetic mice. A:

A: Chemical structure of pterosin A

Systemic treatment with AMPK activators decreases TRPA1 associated with membrane in DRG neurons of db/db mice. Systemic treatment with AMPK activators.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Effect of HA on hematopoietic recovery in tumor-bearing mice.

NSG mice transplanted with human primary ALK-positive ALCL tumor grafts were administered either doxorubicin, 10 mg/kg i.v. or CEP orally, 100 mg/kg,

coTCRcys-transduced T cells control tumor growth in vivo.

mTORC1 is required to prevent cellular senescence.

Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but not OVA Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but.

PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

Quercetin induces arrest in G1 phase of cell cycle in P39 xenografts.

Rapamycin decreases PD-L1 expression in lung tumors in vivo.

Vandetanib decreases tumor incidence and accumulation of HIF-2α, expression of c-Myc and growth factor receptors in the lung of hypoxic mice. Vandetanib.

Bcl-xL expression in tumors antagonizes the therapeutic efficiency of ERBB2 downregulation. Bcl-xL expression in tumors antagonizes the therapeutic efficiency.

Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.

Fig. 1. The HCN channel blocker ivabradine (IVA) is analgesic in a mouse model of type 1 diabetes. The HCN channel blocker ivabradine (IVA) is analgesic.

The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)

Irradiated whole-cell vaccination with MOC1, but not MOC2, induces immunologic memory. Irradiated whole-cell vaccination with MOC1, but not MOC2, induces.

Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model.

Fig. 3. Human liver tissue seed graft function.

A, tumor growth studies in H1975 tumor–bearing mice.

Essential role for the overexpression of type I IFN-related genes in the improved chemotherapeutic response of Stat3−/− tumors. Essential role for the.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

Apoptotic cell index percentage (a and b) and mitotic cell index percentage (c and d) in small intestinal (a and c) and midcolonic (b and d) crypts of.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

PK profile of OTL78. PK profile of OTL78. A, Representative time-dependent whole-body fluorescence images over white light images of a mouse bearing 22Rv1.

YH25448 less suppresses WT EGFR than osimertinib in vivo.

Mean weight change from original weight of (a) BALB/c (b) DBA/2 mice after one (♦) or two (▴) injections of 10 mg/kg and one (▪) or two (×) injections.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

Untargeted LC/MS metabolite profiling of DFMO-treated HT-29 colorectal cancer cells. Untargeted LC/MS metabolite profiling of DFMO-treated HT-29 colorectal.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Wild-type mice weight following 6-thio-dG and 6-thioguanine treatment.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

SW620 xenografts treated with combination siKRAS+siPIK3CA/B.

In vivo effects of TTFields on intradermal tumors in mice.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

PDL192 and inhibit the growth of xenograft tumors.

A, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “sensitive” Ewing.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105. Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105.

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

BV6 increases bone metastasis.

FGFR2 amplification in primary human gastric tumors predicts for response to NVP-BGJ398. FGFR2 amplification in primary human gastric tumors predicts for.

In vivo effect of KIN-193 on PTEN-deficient tumors.

In vivo shRNA screening strategy.

Fig. 5 DDO-5936 dose-dependently impairs the growth of xenografted HCT116 cells in nude mice. DDO-5936 dose-dependently impairs the growth of xenografted.

MET activation confers resistance to cetuximab (Cmab) or panitumumab (Pmab) in colon cancer cell lines in vitro and in vivo. MET activation confers resistance.

Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.

Presentation transcript:

Metabolite profiling of DFMO-treated ApcMin mouse tumors. Metabolite profiling of DFMO-treated ApcMin mouse tumors. ApcMin mice were given DFMO by intraperitoneal injection (40 mg/kg daily) or vehicle (saline) for 21 days and intestinal tumors were microdissected and collected (3 tumors/mouse, n = 4 mice/group). Metabolites were extracted from tumors for analysis by high-performance liquid chromatography, as described in Methods. Along with accumulation of DFMO itself and expected decreases in polyamines, DFMO-treated tissues showed altered expression of methionine cycle and nucleotide/nucleoside levels, similar to in vitro findings (Fig. 3). Notably, this included markedly reduced thymidine levels. *, P < 0.05 by unpaired t test, comparing tumors from untreated and DFMO-treated ApcMin mice. N.D., not detected. Mavee Witherspoon et al. Cancer Discovery 2013;3:1072-1081 ©2013 by American Association for Cancer Research